2. Search Result
Search Result
Results for "

endometrial cancers

" in MedChemExpress (MCE) Product Catalog:

72

Inhibitors & Agonists

1

Peptides

1

MCE Kits

7

Inhibitory Antibodies

8

Natural
Products

3

Isotope-Labeled Compounds

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0141
    Estradiol
    Maximum Cited Publications
    122 Publications Verification

    β-Estradiol; E2; 17β-Estradiol; 17β-Oestradiol

    		 Estrogen Receptor/ERR Endogenous Metabolite Bacterial Endocrinology Cancer
    Estradiol (β-Estradiol) is a steroid hormone and the major female sex hormone. Estradiol can up-regulate the expression of neural markers of human endometrial stem cells (hEnSCs) and promote their neural differentiation. Estradiol can be used for the research of cancers, neurodegenerative diseases and neural tissue engineering .
    Estradiol
  • HY-145572
    Imlunestrant
    1 Publications Verification

    LY-3484356

    		 Estrogen Receptor/ERR Cancer
    Imlunestrant (LY-3484356) is an orally active, potent and selective estrogen receptor degrader (SERD) with pure antagonistic properties. Imlunestrant results in sustained inhibition of ER-dependent gene transcription and cell growth. Imlunestrant can be used for the research of ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC) .
    Imlunestrant
  • HY-169422
    GSK4418959

    IDE275

    		 DNA/RNA Synthesis Cancer
    GSK4418959 (IDE275) is a selective, reversible and orally active WRN helicase inhibitor. GSK4418959 shows >10,000-fold selectivity over other helicases. GSK4418959 inhibits ATPase and DNA unwinding functions in an ATP-competitive manner. GSK4418959 can be used for the study of microsatellite instability-high (MSI-H) cancer, such as colorectal cancer (CRC) and endometrial cancer (EC) .
    GSK4418959
  • HY-103454
    MPP dihydrochloride
    15+ Cited Publications

    		 Estrogen Receptor/ERR Apoptosis Endocrinology Cancer
    MPP dihydrochloride is a potent and selective ER (estrogen receptor) modulator. MPP dihydrochloride induces significant apoptosis in the endometrial cancer and oLE cell lines. MPP dihydrochloride reverses the positive effects of beta-estradiol. MPP dihydrochloride has mixed agonist/antagonist action on murine uterine ERalpha in vivo .
    MPP dihydrochloride
  • HY-B0141R
    Estradiol (Standard)
    Maximum Cited Publications
    122 Publications Verification

    β-Estradiol (Standard); E2 (Standard); 17β-Estradiol (Standard); 17β-Oestradiol (Standard)

    		 Reference Standards Estrogen Receptor/ERR Endogenous Metabolite Bacterial Endocrinology Cancer
    Estradiol (Standard) is the analytical standard of Estradiol. This product is intended for research and analytical applications. Estradiol (β-Estradiol) is a steroid hormone and the major female sex hormone. Estradiol can up-regulate the expression of neural markers of human endometrial stem cells (hEnSCs) and promote their neural differentiation. Estradiol can be used for the research of cancers, neurodegenerative diseases and neural tissue engineering .
    Estradiol (Standard)
  • HY-159607
    PRT3789

    		PROTACs SWI/SNF Complex Cancer
    PRT3789 is a selective SMARCA2 PROTAC degrader (DC50 in HeLa cell: 0.72 nM for SMARCA2, 14 nM for SMARCA4). PRT3789 forms a stable ternary complex with Von Hippel-Lindau (VHL) E3 ligase, induces polyubiquitination at SMARCA2-specific lysine residues, and drives proteasome-dependent SMARCA2 degradation. PRT3789 disrupts SWI/SNF chromatin remodeling complex integrity, induces dissociation of specific subunits, suppresses oncogenic gene expression, reduces chromatin accessibility, and upregulates antigen processing/presentation-related gene expression. PRT3789 induces synthetic lethality, inhibits proliferation and colony formation, and drives tumor growth inhibition and regression in SMARCA4-deficient contexts. PRT3789 can be used for the research of SMARCA4-mutated solid tumors, non-small cell lung cancer, endometrial cancer, colorectal cancer, bladder cancer, esophageal cancer, ovarian cancer, and gastric cancer .
    PRT3789
  • HY-160701
    Cirtociclib
    2 Publications Verification

    BLU-222

    		 CDK Apoptosis Cancer
    Cirtociclib (BLU-222) is an orally active and highly selective CDK2 inhibitor. Cirtociclib disrupts Rb signaling and causes G1 arrest and apoptosis in CCNE1-amplified endometrial cancer cells .
    Cirtociclib
  • HY-145572A
    Imlunestrant tosylate
    1 Publications Verification

    LY-3484356 tosylate

    		 Estrogen Receptor/ERR Cancer
    Imlunestrant (LY-3484356) tosylate is an orally active, potent and selective estrogen receptor degrader (SERD) with pure antagonistic properties. Imlunestrant tosylate results in sustained inhibition of ER-dependent gene transcription and cell growth. Imlunestrant tosylate can be used for the research of ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC) .
    Imlunestrant tosylate
  • HY-16701
    BV6
    20+ Cited Publications

    		 IAP Cancer
    BV6 is an antagonist of cIAP1 and XIAP, members of the inhibitors of apoptosis (IAP) family. BV6 shows an IC50 of 7.2 μM in MTS assays in HCC193 cells. BV6 can be used in the research of endometrial cancer and endometriosis .
    BV6
  • HY-128586
    TAS4464
    5+ Cited Publications

    		 Apoptosis Carbonic Anhydrase NEDD8-activating Enzyme Cancer
    TAS4464 is a long-acting, highly selective covalent inhibitor targeting NEDD8-activating enzyme (NAE) (IC50=0.955 nM), and also inhibits CAII with an IC50 of 0.73 μM, which is less potent than MLN4924 (HY-70062). The IC50 values of TAS4464 against other E1 enzymes UAE and SAE are 449 nM and 1280 nM, respectively. TAS4464 targets NEDD8 in an ATP-dependent manner to inhibit NAE, blocks the neddylation pathway, causes accumulation of CRL ubiquitin ligase substrates (such as CDT1, p27, phosphorylated IκBα), and further induces tumor cell apoptosis. TAS4464 exhibits antiproliferative and cytotoxic effects, and has broad-spectrum antitumor activity against various hematologic and solid tumor cell lines as well as patient-derived tumor cells. TAS4464 has a wide selcetive window, without obvious toxicity. TAS4464 can be used in the research of hematologic malignancies (leukemia, lymphoma, multiple myeloma, etc.) and solid tumors (small cell lung cancer, colorectal cancer, sarcoma, endometrial cancer, ovarian cancer, etc.) .
    TAS4464
  • HY-101466
    E7090

    		FGFR Cancer
    E7090 is an orally available, potent, and selective FGFR inhibitor with IC50s of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/FGFR2/FGFR3/FGFR4, respectively .
    E7090
  • HY-P990717
    Brenetafusp

    IMC-F106C

    		 CD3 Cancer
    Brenetafusp is a TCR/anti-CD3 bispecific fusion protein, consisting of a TCR targeting the PRAME peptide and an anti-CD3 scFv effector domain. Brenetafusp redirects CD3 + T cells to kill PRAME + tumor cells. Brenetafusp can be used in research related to cutaneous melanoma, non-small cell lung cancer, ovarian cancer, endometrial cancer, triple-negative breast cancer, and small cell lung cancer .
    Brenetafusp
  • HY-103454B
    MPP hydrochloride
    15+ Cited Publications

    		 Estrogen Receptor/ERR Apoptosis Endocrinology Cancer
    MPP hydrochloride is a potent and selective ER (estrogen receptor) modulator. MPP hydrochloride induces significant apoptosis in the endometrial cancer and oLE cell lines. MPP hydrochloride reverses the the positive effects of beta-estradiol. MPP hydrochloride has mixed agonist/antagonist action on murine uterine ERalpha in vivo .
    MPP hydrochloride
  • HY-105634A
    Nomegestrol acetate

    		Progesterone Receptor Endocrinology Cancer
    Nomegestrol acetate is an orally active, highly selective progestogen and a progesterone receptor complete agonist. Nomegestrol acetate inhibits ovulation. Nomegestrol acetate is also effective in inhibiting the proliferation of human endometrial cancer RL95-2 cells in vitro and in vivo. Nomegestrol acetate can be used in cancer (especially endometrial cancer) and contraceptive studies .
    Nomegestrol acetate
  • HY-174262
    IL4I1-IN-1

    		Interleukin Related Inflammation/Immunology Cancer
    IL4I1-IN-1 (Compound Ex 232 pg 200) is a selective interleukin 4-induced protein 1 (IL4I1) inhibitor with an EC50 of 2 nM. IL4I1-IN-1 inhibits IL4I1-mediated oxidative deamination of phenylalanine, reducing the production of phenylpyruvate, H2O2 and NH3. IL4I1-IN-1 is promising for research of cancers with high IL4I1 expression, such as endometrial carcinoma, ovarian cancer, and triple-negative breast cancer .
    IL4I1-IN-1
  • HY-N0818
    Chikusetsusaponin Iva
    2 Publications Verification

    Calenduloside F

    		 Keap1-Nrf2 Infection Metabolic Disease Endocrinology Cancer
    Chikusetsusaponin IVa is an orally active protein kinase activator. Chikusetsusaponin IVa binds to YAP with a KD value of 0.388 mM. Chikusetsusaponin IVa reduces inflammatory mediators (IL-6, IL-10, COX-2) expression, NO production, promotes ROS generation, induces Apoptosis, inhibits MAPK, TAZ, and regulates Nrf2, JAK/STAT. Chikusetsusaponin Iva has anti-H9N2 AIV and anti-endometrial cancer activities. Chikusetsusaponin Iva shows anti-inflammatory, hepatoprotective and osteoprotective effects .
    Chikusetsusaponin Iva
  • HY-145584
    Nesuparib

    JPI-547/OCN-201

    		 PARP Wnt β-catenin Neurological Disease Cancer
    Nesuparib (JPI-547) is the orally active inhibitor for PARP 1/2 and Tankyrase 1/2 that inhibits tankyrases 1, tankyrases 2, and PARP 1 with IC50s of 5, 1 and 2 nM, respectively. Nesuparib exhibits antitumor activity and can be used in research of advanced solid tumor .
    Nesuparib
  • HY-164664
    CDK2-IN-30

    		CDK Cancer
    CDK2-IN-30 is a CDK2 inhibitor with an IC50 value ≤20 nM. CDK2-IN-30 modulates CDK2 activity to influence cell cycle regulation. CDK2-IN-30 can be used for the research of cancer .
    CDK2-IN-30
  • HY-N0864
    Macranthoidin B

    Macranthoiside I

    		 Apoptosis COX Reactive Oxygen Species (ROS) Caspase SOD Cancer
    Macranthoidin B (Macranthoiside I) is an orally active triterpene saponin. Macranthoidin B inhibits epithelial-mesenchymal transition in endometriosis via the COX‑2/PGE2 pathway, and also induces tumor cell apoptosis and inhibits their proliferation by regulating metabolism and increasing ROS levels . Macranthoidin B can be used in studies related to endometriosis, colorectal cancer and hepatocellular carcinoma .
    Macranthoidin B
  • HY-111614
    Melengestrol acetate

    		Progesterone Receptor Metabolic Disease Cancer
    Melengestrol acetate is a progesterone derivative, acts as an orally active corticosteroid hormone to promote endometrial proliferation, pregnancy maintenance, and delay of menstrual activity . Melengestrol Acetate is used as a contraceptive agent for growth promoting effects and suppression of estrus in animals. Melengestrol acetate inhibits both the androgen-dependent and -independent prostatic tumors in vivo and can be used for cancer research .
    Melengestrol acetate
  • HY-B0984
    Fendiline hydrochloride
    3 Publications Verification

    		 Calcium Channel Ras STING Autophagy Infection Cardiovascular Disease Cancer
    Fendiline hydrochloride, a diphenylalkylamine type of antianginal agent, is an L-type calcium channel blocker (IC50 of 17 µM). Fendiline hydrochloride is also a selective K-Ras inhibitor, and has no effect on H-Ras and N-Ras. Fendiline hydrochloride inhibits K-Ras plasma membrane localization (IC50 of 9.64 μM), inhibits K-Ras signal output and blocks the proliferation of pancreatic, colon, lung, and endometrial cancer cell lines expressing oncogenic mutant K-Ras. Fendiline hydrochloride is a STING agonist and is able to inhibit the growth of multiple refractory cold tumors (MC38, CT26 and B16F10) .
    Fendiline hydrochloride
  • HY-128586A
    TAS4464 hydrochloride
    5+ Cited Publications

    		 NEDD8-activating Enzyme Carbonic Anhydrase Apoptosis Cancer
    TAS4464 hydrochloride is a long-acting, highly selective covalent inhibitor targeting NEDD8-activating enzyme (NAE) (IC50=0.955 nM), and also inhibits CAII with an IC50 of 0.73 μM, which is less potent than MLN4924 (HY-70062). The IC50 values of TAS4464 hydrochloride against other E1 enzymes UAE and SAE are 449 nM and 1280 nM, respectively. TAS4464 hydrochloride targets NEDD8 in an ATP-dependent manner to inhibit NAE, blocks the neddylation pathway, causes accumulation of CRL ubiquitin ligase substrates (such as CDT1, p27, phosphorylated IκBα), and further induces tumor cell apoptosis. TAS4464 hydrochloride exhibits antiproliferative and cytotoxic effects, and has broad-spectrum antitumor activity against various hematologic and solid tumor cell lines as well as patient-derived tumor cells. TAS4464 hydrochloride has a wide therapeutic window, without obvious toxicity. TAS4464 hydrochloride can be used in the research of hematologic malignancies (leukemia, lymphoma, multiple myeloma, etc.) and solid tumors (small cell lung cancer, colorectal cancer, sarcoma, endometrial cancer, ovarian cancer, etc.) .
    TAS4464 hydrochloride
  • HY-16441
    Tegafur-gimeracil-oteracil potassium

    S-1; TS-1

    		 PI3K Akt mTOR Apoptosis Bcl-2 Family Cancer
    Tegafur-gimeracil-oteracil potassium (S-1; TS-1) is an orally active anticancer agent composed of Tegafur (HY-17400), Gimeracil (HY-17469), and Oteracil potassium (HY-17511). Tegafur-gimeracil-oteracil potassium inhibits the proliferation, migration and invasion of endometrial cancer cells and induces apoptosis by blocking the PI3K/AKT/mTOR signaling pathway. Tegafur-gimeracil-oteracil potassium can be used in research related to endometrial cancer and gastric cancer with peritoneal metastasis .
    Tegafur-gimeracil-oteracil potassium
  • HY-P990704
    Rilvegostomig

    AZD-2936

    		 PD-1/PD-L1 Transmembrane Glycoprotein Cancer
    Rilvegostomig (AZD-2936) is a bispecific humanized IgG1 antibody targeting PD-1 and TIGIT. Rilvegostomig induces tumor growth inhibition and modulates the tumor immune microenvironment. Rilvegostomig exhibits anti-tumor activity in metastatic non-small cell lung cancer (without prior immune checkpoint inhibitor treatment). Rilvegostomig can be used in research related to metastatic non-small cell lung cancer and endometrial cancer .
    Rilvegostomig
  • HY-12825
    BHPI

    		Estrogen Receptor/ERR Phospholipase Cancer
    BHPI is a nuclear receptor ERα inhibitor. BHPI activates PLCγ and UPR. BHPI has antitumor activity against breast, endometrial, and ovarian cancers .
    BHPI
  • HY-B0141C
    Estradiol hemihydrate
    Maximum Cited Publications
    122 Publications Verification

    β-Estradiol hemihydrate; 17β-Estradiol hemihydrate; 17β-Oestradiol hemihydrate

    		 Estrogen Receptor/ERR Endogenous Metabolite Bacterial Neurological Disease Cancer
    Estradiol (β-Estradiol) hemihydrate is a steroid hormone and the major female sex hormone. Estradiol (β-Estradiol) hemihydrate can up-regulate the expression of neural markers of human endometrial stem cells (hEnSCs) and promote their neural differentiation. Estradiol (β-Estradiol) hemihydrate can be used for the research of cancers, neurodegenerative diseases and neural tissue engineering .
    Estradiol hemihydrate
  • HY-111614S2
    Melengestrol acetate-d3

    		Isotope-Labeled Compounds Progesterone Receptor Metabolic Disease Cancer
    Melengestrol acetate-d3 is the deuterium labeled Melengestrol acetate. Melengestrol acetate is a progesterone derivative, acts as an orally active corticosteroid hormone to promote endometrial proliferation, pregnancy maintenance, and delay of menstrual activity . Melengestrol Acetate is used as a contraceptive agent for growth promoting effects and suppression of estrus in animals. Melengestrol acetate inhibits both the androgen-dependent and -independent prostatic tumors in vivo and can be used for cancer research .
    Melengestrol acetate-d3
  • HY-B0984A
    Fendiline
    3 Publications Verification

    		 Calcium Channel Ras STING Autophagy Infection Cardiovascular Disease Cancer
    Fendiline, a diphenylalkylamine type of antianginal agent, is an L-type calcium channel blocker (IC50 of 17 µM). Fendiline is also a selective K-Ras inhibitor, and has no effect on H-Ras and N-Ras. Fendiline inhibits K-Ras plasma membrane localization (IC50 of 9.64 μM), inhibits K-Ras signal output and blocks the proliferation of pancreatic, colon, lung, and endometrial cancer cell lines expressing oncogenic mutant K-Ras. Fendiline is a STING agonist and is able to inhibit the growth of multiple refractory cold tumors (MC38, CT26 and B16F10) .
    Fendiline
  • HY-P99463
    Batiraxcept
    2 Publications Verification

    AVB-500; AVB-S6-500

    		 TAM Receptor PI3K Akt p38 MAPK Cancer
    Batiraxcept (AVB-500; AVB-S6-500) is a selective, soluble AXL receptor and GAS6 inhibitor that targets the GAS6-AXL signaling axis. Batiraxcept is orally inactive and does not cross the blood-brain barrier. Batiraxcept competitively binds to GAS6 ((KD <1 nM), preventing its interaction with the AXL receptor tyrosine kinase, thereby inhibiting downstream PI3K/AKT and MAPK signaling pathways, reducing tumor cell glycolysis, angiogenesis, and metastatic potential. Batiraxcept has demonstrated antitumor activity in preclinical models of endometrial, cholangiocarcinoma, and ovarian cancer by inhibiting tumor growth, invasion, and metastasis .
    Batiraxcept
  • HY-P991703
    Mocertatug

    GSK5733584 antibody; HS-20089 antibody; hu2F7

    		 CD276/B7-H3 Cancer
    Mocertatug (GSK5733584 antibody) is a humanized IgG1κ antibody targeting B7-H4/VTCN1. Mocertatug can be used to construct ADCs, such as Mocertatug Rezetecan (HY-185280) .
    Mocertatug
  • HY-175743
    TYRA-200

    		FGFR Cancer
    TYRA-200 is a potent and orally active FGFR2 inhibitor. TYRA-200 inhibits the kinase activity of wild-type FGFR2 and its mutants. TYRA-200 induces significant tumor regression in FGFR2-driven cancer models. TYRA-200 can be used for the research of FGFR2-altered advanced solid tumors, intrahepatic cholangiocarcinoma, and endometrial cancer .
    TYRA-200
  • HY-N7148A
    (±)-γ-Tocopherol

    		Endogenous Metabolite Cancer
    (±)-γ-Tocopherol is an endogenous metabolite present in Blood that can be used for the research of Prostate Cancer and Endometrial Cancer .
    (±)-γ-Tocopherol
  • HY-161024
    AC1Q3QWB

    AQB

    		 Histone Methyltransferase Cancer
    AC1Q3QWB upregulates CDKN1A and SOX17 by interrupting the HOTAIR-EZH2 interaction and enhances the efficacy of Tazemetostat in endometrial cancer .
    AC1Q3QWB
  • HY-177542
    Emiltatug ledadotin

    Emi-Le; XMT-1660

    		 Cancer
    Emiltatug ledadotin (Emi-Le; XMT-1660) is a B7-H4-targeted antibody-drug conjugate (ADC). Emiltatug ledadotin consists of the tumor-specific anti-B7-H4 monoclonal antibody Emiltatug (HY-P990918) and the linker-payload system Ledadotin (HY-177541), with site-specific conjugation achieved via GlycoConnect click chemistry. Emiltatug ledadotin inhibits the growth of B7-H4-positive cancer cells. Emiltatug ledadotin can be used to study advanced solid tumors with B7-H4 overexpression, particularly breast cancer, ovarian cancer, and endometrial cancer .
    Emiltatug ledadotin
  • HY-B1341
    Norethynodrel

    Enidrel; SC-4642; NSC 15432

    		 Endogenous Metabolite Progesterone Receptor Cancer
    Norethynodrel (Enidrel; SC-4642) is an orally active progestogen analog that reduces estrogen-like effects and enhances progestogen-like responses in endometrial stromal cells. Norethynodrel also promotes cell maturation and predecidual cell formation by inducing organelle hyperplasia and glycogen accumulation. Norethynodrel competitively inhibits drug-metabolizing enzymes in rat liver microsomes, thereby prolonging Pentobarbital sleep time, while exhibiting multiple effects including reduced body weight gain, attenuated heart rate elevation and ovulation inhibition. In mouse models, Norethynodrel significantly increases the incidence of mammary adenocarcinoma, cervical cancer and pituitary tumors. Norethynodrel can be used for mechanism research on related diseases such as mammary adenocarcinoma, cervical cancer, ovarian tubular adenoma and pituitary adenoma .
    Norethynodrel
  • HY-B0984R
    Fendiline hydrochloride (Standard)

    		Calcium Channel Ras STING Autophagy Reference Standards Infection Cardiovascular Disease Cancer
    Fendiline (hydrochloride) (Standard) is the analytical standard of Fendiline (hydrochloride). This product is intended for research and analytical applications. Fendiline hydrochloride, a diphenylalkylamine type of antianginal agent, is an L-type calcium channel blocker (IC50 of 17 µM). Fendiline hydrochloride is also a selective K-Ras inhibitor, and has no effect on H-Ras and N-Ras. Fendiline hydrochloride inhibits K-Ras plasma membrane localization (IC50 of 9.64 μM), inhibits K-Ras signal output and blocks the proliferation of pancreatic, colon, lung, and endometrial cancer cell lines expressing oncogenic mutant K-Ras. Fendiline hydrochloride is a STING agonist and is able to inhibit the growth of multiple refractory cold tumors (MC38, CT26 and B16F10) .
    Fendiline hydrochloride (Standard)
  • HY-176774
    L07-2

    		Toll-like Receptor (TLR) NF-κB Cancer
    L07-2 is a TLR7/8 agonist. L07-2 is a linker-toxin building block that can be used to synthesize immunostimulatory antibody conjugates (ISACs) for cancer research. L07-2 can be used to studies related to tumors such as non-small cell lung cancer .
    L07-2
  • HY-159613
    PELP1-IN-1

    		Apoptosis Estrogen Receptor/ERR Inflammation/Immunology Cancer
    PELP1-IN-1 is a PELP1 inhibitor and an apoptosis inducer with no cytotoxic activity against non-cancer cell lines. PELP1-IN-1 targets wild-type, mutant and drug-resistant ER + breast cancer, and promotes PELP1 degradation through the proteasome pathway. As an analog of SMIP34 (HY-169903), PELP1-IN-1 is applicable to the research of estrogen receptor α-positive breast cancer .
    PELP1-IN-1
  • HY-162774A
    GRP75-IN-1 dihydrochloride

    		Apoptosis Cancer
    GRP75-IN-1 hydrochloride (compound 33) is an anti-endometrial cancer (EC) agent that induces apoptosis. GRP75-IN-1 hydrochloride reduces Ca 2+ levels in mitochondria by targeting GRP75 and disrupting its interaction with IP3R .
    GRP75-IN-1 dihydrochloride
  • HY-P990860
    Anti-CD40 Antibody (G28.5)

    		TNF Receptor Cancer
    Anti-CD40 Antibody (G28.5) is a kind of mouse IgG1 κ chimeric agonistic antibody, targeting to human CD40. Anti-CD40 Antibody (G28.5) can activate CD40 signaling and promote anti-tumor T cell responses. Anti-CD40 Antibody (G28.5) can be used for the research of cancer, such as endometrial cancer .
    Anti-CD40 Antibody (G28.5)
  • HY-177146
    Paclitaxel-MVCP

    MC-Val-Cit-PAB-Paclitaxel

    		 Drug-Linker Conjugates for ADC Cancer
    Paclitaxel-MVCP (MC-Val-Cit-PAB-Paclitaxel) is a MC-Val-Cit-PAB (HY-78738) and Paclitaxel (HY-B0015) conjugate, and can be used for synthesis of Paclitaxel-nucleolin aptamer conjugate .
    Paclitaxel-MVCP
  • HY-157165
    Tubulin/PARP-IN-1

    		Microtubule/Tubulin PARP Cancer
    Tubulin/PARP-IN-1 (compound 14) is a dual PARP-tubulin inhibitor with activity against endometrial cancer. Tubulin/PARP-IN-1 inhibits PARP and tubulin with IC50s of 74 nM (PARP1), 109 nM (PARP2), and 1.4 μM (Microtubule/Tubulin), respectively. Tubulin/PARP-IN-1 can induce apoptosis and autophagy and cause cell cycle arrest in the G2/M phase .
    Tubulin/PARP-IN-1
  • HY-162774
    GRP75-IN-1

    		Apoptosis Cancer
    GRP75-IN-1 (Compound 33) is an anti-endometrial cancer (EC) agent. GRP75-IN-1 induces apoptosis in endometrial cancer cells. GRP75-IN-1 hydrochloride reduces mitochondrial Ca 2+ levels by targeting GRP75 and disrupting its interaction with IP3R. GRP75-IN-1 inhibits tumor growth in human endometrial cancer xenograft animal models. GRP75-IN-1 can be used for research in endometrial cancer .
    GRP75-IN-1
  • HY-U00091
    Gestonorone Capronate

    Gestonorone caproate

    		 Progesterone Receptor Cancer
    Gestonorone Capronate is a progestin for the treatment of benign prostatic hypertrophy and endometrial cancer.
    Gestonorone Capronate
  • HY-16701A
    BV6 TFA
    20+ Cited Publications

    		 IAP Cancer
    BV6 TFA is an antagonist of cIAP1 and XIAP, members of the inhibitors of apoptosis (IAP) family. BV6 TFA shows an IC50 of 7.2 μM in MTS assays in HCC193 cells. BV6 TFA can be used in the research of endometrial cancer and endometriosis .
    BV6 TFA
  • HY-179129
    AKT-100

    		MDM-2/p53 Cancer
    AKT-100 is a p53 reactivation agent. AKT-100 significantly inhibits the proliferation of various ovarian and endometrial cancer cells at low concentrations. AKT-100 can upregulate cell cycle regulatory genes (such as p21, GADD45) and pro apoptotic genes (such as NOXA, DR5), and inhibit DNA repair pathways. AKT-100 is commonly used in cancer research .
    AKT-100
  • HY-127133
    Methylpiperidino pyrazole

    MPP

    		 Estrogen Receptor/ERR Endocrinology
    Methylpiperidino pyrazole (MPP) is a potent and selective ER (estrogen receptor) modulator. Methylpiperidino pyrazole induces significant apoptosis in the endometrial cancer and oLE cell lines. Methylpiperidino pyrazole reverses the the positive effects of beta-estradiol. Methylpiperidino pyrazole has mixed agonist/antagonist action on murine uterine ERalpha in vivo .
    Methylpiperidino pyrazole
  • HY-N12044
    Asparanin A

    		Apoptosis Cancer
    Asparanin A is an apoptosis inducer with anticancer activity. Asparanin A induces cell cycle arrest in the G0/G1 phase through mitochondria and PI3K/AKT signaling pathways, inhibiting cancer cell growth. Asparanin A also demonstrated in vivo efficacy in a mouse xenograft model of Ishikawa endometrial carcinoma, significantly inhibiting tumor growth .
    Asparanin A
  • HY-P99881
    Rolinsatamab talirine

    ABBV 176

    		 Antibody-Drug Conjugates (ADCs) Cancer
    Rolinsatamab talirine (ABBV 176) is a prolactin receptor (PRLR)-targeting antibody-drug conjugate (ADC), compoused of Rolinsatamab (HY-P99238) and SGD-1882 (HY-101127). Rolinsatamab talirine binds to PRLR to deliver a cytotoxin to tumor cells. Rolinsatamab talirine induces DNA damage, and exhibits cytotoxicity against multiple breast tumor models, including triple negative and low PRLR-expressing models. Rolinsatamab talirine demonstrates enhanced anti-tumor activity in several breast cancer models. Rolinsatamab talirine can be used for the research of breast cancer, hepatocellular carcinoma, ovarian cancer, endometrial cancer, prostate cancer, colorectal cancer, adrenocortical carcinoma, and solid tumors .
    Rolinsatamab talirine
  • HY-101466A
    E7090 succinate

    		FGFR Cancer
    E7090 succinate is an orally available, selective and potent inhibitor of FGFR1, FGFR2 and FGFR3 tyrosine kinase activities, with IC50 values of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/2/3/4, respectively .
    E7090 succinate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: